Moderna, Inc. (NASDAQ:MRNA) Holdings Lowered by Schroder Investment Management Group

Schroder Investment Management Group trimmed its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 76.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 32,104 shares of the company's stock after selling 103,486 shares during the period. Schroder Investment Management Group's holdings in Moderna were worth $1,264,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Moderna in the fourth quarter worth about $163,833,000. State Street Corp lifted its position in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in Moderna by 170.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock worth $73,447,000 after acquiring an additional 1,113,455 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock worth $349,166,000 after acquiring an additional 906,114 shares during the period. Finally, Amundi grew its position in Moderna by 79.8% in the fourth quarter. Amundi now owns 1,206,273 shares of the company's stock valued at $52,075,000 after acquiring an additional 535,273 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MRNA. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. JPMorgan Chase & Co. decreased their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Friday, March 21st. Citigroup began coverage on Moderna in a research note on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price for the company. UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Finally, Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $58.70.

Moderna Price Performance

Shares of NASDAQ:MRNA traded up $1.70 during trading on Friday, reaching $26.20. 10,999,018 shares of the company's stock traded hands, compared to its average volume of 7,181,056. The stock has a market capitalization of $10.13 billion, a P/E ratio of -2.82 and a beta of 2.23. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47. The company has a 50 day moving average of $31.56 and a 200-day moving average of $41.01.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.